Canopy's 13% Revenue Gain Fails to Convince a Skeptical Market

What happened

Canopy Growth reported a 13% year-over-year revenue increase in its most recent quarter, driven by continued strength in Canadian adult-use and medical cannabis. Adjusted gross margin improved and EBITDA losses narrowed sharply, but the company remains deeply unprofitable on a GAAP basis and still burns cash. Investors barely reacted, with shares trading near $1.28, reflecting persistent skepticism about the durability of the turnaround and the impact of proposed medical reimbursement cuts. The market appears to be discounting the improvement because it is largely cost-driven and acquisition-dependent, with the pending MTL Cannabis deal adding uncertainty rather than immediate clarity. Until Canopy demonstrates sustained positive free cash flow and EBITDA breakeven without relying on further share issuance, the stock is likely to remain rangebound and headline-sensitive.

Implication

The muted stock reaction suggests that the market has already priced in near-term balance-sheet repair and is demanding proof of self-funded profitability. Investors should monitor whether the revenue growth is accompanied by gross margin expansion from pricing power rather than cost cuts or mix shifts. The proposed Canadian medical reimbursement cuts remain a key risk that could reverse recent top-line gains if implemented without offsetting actions. Continued reliance on ATM share issuance to fund operations or close the MTL deal would dilute existing holders and signal that the turnaround is not yet self-sustaining. Only after two consecutive quarters of positive adjusted EBITDA and shrinking free cash flow burn would we consider upgrading from WAIT.

Thesis delta

The thesis remains unchanged: Canopy is a speculative turnaround story with improving operations but unproven sustainability. The 13% revenue gain and narrower losses are positive but do not yet alter the probability-weighted view that the stock is fairly valued around $1.60 in the base case. We maintain a WAIT rating and would reassess only upon sustained EBITDA breakeven or a material deterioration in the balance sheet.